You are here

Article Text

Article menu
Download PDFPDF
LETTER
Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn
  1. A G Cleary1,
  2. B Brown1,
  3. J Minards1,
  4. J Sills1,
  5. P Bolton-Maggs2
  1. 1Royal Liverpool Children’s Hospital, Liverpool, UK; gavin.cleary@rlch-tr.nwest.nhs.uk
  2. 2Manchester Haemophilia Comprehensive Care Centre, Department of Clinical Haematology, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK

    https://doi.org/10.1136/fn.88.5.F444-a

    Statistics from Altmetric.com

      Request Permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

      We read with interest the recent review of Gottstein and Cooke.1 Their systematic review of trials reporting treatment of infants with proven Rh and/or ABO haemolytic disease of the newborn (HDN) treated with high dose intravenous immunoglobulin (HDIVIG) and phototherapy, with phototherapy alone demonstrated that significantly fewer infants required exchange transfusion in the HDIVIG group. The authors point out that anti-D is the commonest red cell antibody responsible for HDN. We have recently treated two children both of whom developed evidence of immune haemolysis due to anti-D antibodies acquired from IVIG.

      The …

      View Full Text